Biocon Academy Achieves 100% Placement within 2.5 hours for Quality Control Analytical Program

& Biocon Academy also Concludes 5th edition of MCADDI – 5-day Residential Program for Industry Experts

Bengaluru, November 14, 2024

Biocon Academy announced a remarkable 100% placement success for Batch 6 of the Biocon Ramaiah Certificate Program in Quality Control Analytical, achieved in a record 2.5 hours. This milestone highlights the Academy’s high training standards and strong demand for its graduates.

The placement drive attracted top companies, including Biocon, Biocon Biologics, Syngene, RL Fine Chem, Dr. Reddy’s Laboratories, and Baxter. Students have secured roles in Quality Control, Analytical Research and Development, and Product Surveillance departments. About 80% of the batch are female students.

Bindu Ajit, Program Dean, Biocon Academy, “I am delighted to see our students succeed—a testament to our commitment to quality and innovation. Our rigorous training, including functional visits, hands-on sessions and mock interviews, has broadened their learning horizons and prepared them for corporate life. By unlearning old concepts and embracing new knowledge, they have developed the professional skills and confidence needed in the industry. Congratulations to our students, and all the best for their future endeavours.”

Ramgopal Rao S, Senior Academic Manager and Coordinator for Biocon Ramaiah Certificate Program in Quality Control Analytical, Biocon Academy said, “It is wonderful to see all the students from QCA Batch 6 secure placements on the first day in esteemed companies such as Baxter, Dr. Reddy’s, Biocon, Biocon Biologics, Syngene, and RL Fine Chem, across both Quality Control and Analytical R&D departments. This achievement is a true testament to the skill development initiatives we at Biocon Academy are proudly committed to. As the course coordinator and trainer, it was incredibly rewarding to witness these young professionals land their first jobs on day one. Wishing them every success, and I am confident they will go on to be proud ambassadors of Biocon Academy.”

Biocon Academy’s tailored curriculum, developed in partnership with Ramaiah Institute, ensures students are equipped with a comprehensive foundation in Quality Control Analytical techniques and receives practical training. Thus, empowering students with the skills that companies in the biotech and pharmaceutical sectors are actively seeking.

Medicinal Chemistry, Drug Discovery & Development India (MCADDI) 2024

Biocon Academy recently concluded the 5^th edition of 5-day residential course in ‘Medicinal Chemistry, Drug Discovery & Development India (MCADDI) 2024’, in association with the American Chemical Society, Division of Medicinal Chemistry (ACSMEDI), Pharma Innovation Sourcing Centre LLC USA, International Union of Applied and Pure Chemistry (IUPAC), and ACS Publications.

Salavadi Easwaran, Academic Dean, Biocon Academy said “At Biocon Academy, our aim has always been to bridge the gap between industry and academia by delivering programs that equip aspiring professionals with industry-relevant skills. MCADDI 2024 provided a platform to participants to interact with leading experts in drug discovery and development, engage in insightful discussions on the latest advancements in medicinal chemistry and a lot more. This unique exposure helps them build a strong foundation for a successful career in the biotech sectors; positions them to meet the evolving demands and contribute meaningfully to global healthcare solutions.”

The program was attended by approximately 100 participants and led by 15 experts who conducted 32 impactful sessions on lead optimization, molecular modelling, in silico tools for medicinal chemistry, the role of heterocycles in drug design, and structure-based approaches to drug development. Innovative 3D lectures and interactive case studies were the limelight of the course, which gave hands-on experience and a deeper understanding of modern drug discovery to the participants.

An illustrious line-up of speakers from industry and academia included Thomas Prisinzano (University of Kentucky, U.S.), Manjunath Ramarao (Atomic AI, U.S.), Vincent S Stoll (AbbVie, U.S.), Nicholas A. Meanwell (Baruch S. Blumberg Institute, U.S.) , Mukul Jain (Zydus, India), Bruce Ellsworth (Bristol – Myers Squibb, U.S.), H. Rachel Lagiakos (Schrodinger, U.S.), Rustom Mody (Sun Pharma, India), Nitin Damle (Sun Pharma, India), Sridhar Desikan (Nexus Pharma, India), Martin Eastgate (Bristol – Myers Squibb, U.S.), Sandhya Mandlekar (Genentech, U.S.), and Nagaraj Gowda (Glenmark Pharmaceuticals).

Aimed at pushing boundaries through innovative thinking and strategic collaborations in the field of drug discovery and development, MCADDI 2024 reaffirmed Biocon Academy’s commitment to shaping the future of healthcare in India and beyond.

About Biocon Academy

Biocon Academy, a Centre of Excellence for Advanced Learning in Biosciences, is a CSR initiative of Biocon, Asia’s leading biopharmaceutical company. It is aimed at developing high-end, industry-ready, talent for the Indian biotech sector to address the skill deficit. The Academy aims at enhancing the employability of bioscience graduates by providing them advanced experiential learning through practical training. It has been instrumental in shaping careers of aspiring biotech graduates while bridging the industry-academia gap. The Academy has collaborated with leading global institutes like Keck Graduate Institute, California, USA, BITS Pilani, India, MS Ramaiah College of Arts, Science and Commerce, Bengaluru, India, and JSS AHER, Mysuru, India, to offer global quality learning to the students of Biocon Academy. Biocon offers scholarships that cover 60 – 75% of the cost of these international programs. For more information, visit www.bioconacademy.com